**Name of Journal:** *World Journal of Clinical Cases*

**Manuscript NO:** 72142

**Manuscript Type:** ORIGINAL ARTICLE

***Retrospective Study***

**Clinical effect of methimazole combined with selenium in the treatment of toxic diffuse goiter in children**

Zhang XH *et al*. Methimazole combined with selenium in toxic diffuse goiter

Xiao-Hong Zhang, Gao-Pin Yuan, Ting-Li Chen

**Xiao-Hong Zhang, Gao-Pin Yuan, Ting-Li Chen,** Department of Pediatric Endocrinology, Quanzhou Women and Children’s Hospital, Quanzhou 362000, Fujian Province, China

**Author contributions:** Zhang XH, Yuan GP, and Chen TL designed and performed the study; Zhang XH, Yuan GP, and Chen TL analyzed the data; and all authors contributed to the writing and revising of the manuscript.

**Corresponding author: Xiao-Hong Zhang, MD, Doctor,** Department of Pediatric Endocrinology, Quanzhou Women and Children’s Hospital, No. 700 Fengze Street, Quanzhou 362000, Fujian Province, China. zhangxiaohong2109@163.com

**Received:** October 22, 2021

**Revised:** December 1, 2021

**Accepted:** December 22, 2021

**Published online:** February 6, 2022

**Abstract**

BACKGROUND

The incidence of toxic diffuse goiter (Graves’ disease) is higher in adolescents and preschool-aged children, with an upward trend. The incidence at 6–13 years of age is approximately 11.0%, and the incidences in men and women are 7.8% and 14.3%, respectively.

AIM

To explore the clinical effect of methimazole combined with selenium in the treatment of toxic diffuse goiter (Graves’ disease) in children and its effect on serum anti-thyroglobulin antibody (TRAb) and anti-thyroid peroxidase antibody (TPOAb).

METHODS

A total of 103 children with Graves’ disease treated in our hospital from January 2018 to June 2021 were divided into a traditional group and a combined group (15-20 mg methimazole orally given to children) and a combined group (50 µg selenium added on the basis of traditional treatment) according to different treatment methods to explore the therapeutic effects of the two methods and to observe the changes in thyroid volume and serum TRAb, TPOAb, free thyroxine (FT4) and inflammatory factor levels before and after treatment. The time taken for FT4 to return to normal was compared between the two groups.

RESULTS

Treatment was significantly more effective in the combined group than in the traditional group (*P* < 0.05). The thyroid volumes of the children in the two groups was measured before and after treatment. Thyroid volume decreased significantly after treatment in both groups, and the thyroid volume was significantly lower in the combined group than in the traditional group (*P* < 0.05). The serum levels of interleukin-6 (IL-6), IL-8, TRAb, TPOAb and FT4 in the two groups were detected before and after treatment. The levels of IL-6, IL-8, TRAb, TPOAb and FT4 were significantly lower in the combined group than in the traditional group (*P* < 0.05). Follow-up of the children in the two groups showed that compared with the traditional group, it took less time for children in the combined group to return to the normal level (*P* < 0.05).

CONCLUSION

Methimazole combined with selenium can effectively treat Graves’ disease in children, reduce the expression of TRAb, TPOAb, FT4 and inflammatory factors, and improve the curative effect. Thus, the combined treatment warrants further clinical research.

**Key Words:** Methimazole; Selenium; Children; Antithyroid globulin; Anti-thyroid peroxidase antibody

**©The** **Author(s) 2022.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Citation:** Zhang XH, Yuan GP, Chen TL. Clinical effect of methimazole combined with selenium in the treatment of toxic diffuse goiter in children. *World J Clin Cases* 2022; 10(4): 1190-1197

**URL:** <https://www.wjgnet.com/2307-8960/full/v10/i4/1190.htm>

**DOI:** https://dx.doi.org/10.12998/wjcc.v10.i4.1190

**Core Tip:** Anti-thyroglobulin (thyroglobulin antibody, TRAb) is a common antibody in the sera of children with autoimmune thyroid disease, and anti-thyroid peroxidase antibody (thyroid peroxidase antibody, TPOAb) is an indicator closely related to thyroid immune damage. In this study, 103 children with Graves’ disease treated in our hospital were selected and divided into a traditional group and a combined group according to treatment method to explore the therapeutic effects of the two methods and to detect changes in serum TRAb and TPOAb levels of the two groups of children before and after treatment. The clinical efficacy of the combined treatment provides a solid theoretical foundation for the clinical diagnosis and treatment of Graves.

**INTRODUCTION**

Toxic diffuse goiter (Graves) is an organ-specific autoimmune disease accompanied by increased secretion of thyroid hormone. It is the most common autoimmune thyroid disease in children. The main clinical symptoms are goiter, pain, and emotional agitation[1]. The enlarged thyroid gland is symmetrical and has a lobulated appearance. The texture of the enlarged gland is as tough as rubber. Some children will have symptoms of hyperthyroidism, and later symptoms of hypothyroidism may seriously affect the child’s physical and mental health. Therefore, timely and effective diagnosis and treatment are important for the child’s condition and prognosis[2,3]. In recent years, methimazole has been widely used in the clinical treatment of Graves. Methimazole is a thyroid disease drug that inhibits the synthesis of thyroxine and improves thyroid function. However, due to children’s physique and drug control problems[4], side effects of methimazole occur frequently in children. Selenium is an essential trace element for the human body. Selenium is closely related to thyroid gland function and can improve the antioxidant capacity of the thyroid gland and curb hypothyroidism. Selenium can inhibit the activity of thyroid hormone receptors, reduce the probability of thyroid hormone binding, reduce the basal metabolic rate, and inhibit the occurrence and development of thyroid diseases[5].

**MATERIALS AND METHODS**

***General information***

A total of 103 children with Graves’ disease who were treated in our hospital from January 2018 to June 2021 were selected and divided into a traditional group and a combined group according to their different treatment methods. There were 50 children in the traditional group, including 28 males and 22 females, with an average age of 7.85 ± 1.23 years, a course of 2 to 4 years, and an average course of 2.84 ± 0.31 years. There were 53 children in the combined group, including 26 males and 27 females, with an average age of 7.49 ± 1.21 years, a course of 2 to 4 years, and an average course of 2.91 ± 0.35 years. The inclusion criteria were as follows[7]: (1) Meet the standards in "Internal Medicine. Endocrinology Division": (a) Clinical manifestations of thyrotoxicosis; (b) B-ultrasound of the thyroid gland suggesting diffuse thyroid enlargement; (c) thyroid stimulating hormone is reduced, and free triiodothyronine and free thyroxine (FT4) are elevated; (d) exophthalmos and other infiltrating eye signs; (e) anterior tibial mucinous edema; and (f) positive for thyroglobulin antibody (TRAb) or thyroid stimulating antibody. Criteria (a), (b), and (c) are a necessary diagnosis, and criteria (d), (e), and (f) are an auxiliary diagnosis; (2) first treatment; (3) age 4-13 years; and (4) complete information. The exclusion criteria were as follows: (1) thyroid hyperfunctioning adenoma; (2) toxic nodular goiter; (3) transient hyperthyroidism such as subacute thyroiditis, Hashimoto’s disease, painless thyroiditis, *etc*.; (4) medical history of malignant thyroid tumor; (5) previous thyroid surgery or 131 iodine therapy; (6) reduced white blood cells and impaired liver function; and (7) other autoimmune diseases.

***Treatment and testing methods***

Children in the traditional group received 15–20 mg of methimazole (Merck Pharmaceuticals (Jiangsu) Co., Ltd., National Medicine Standard: J20171078),1 time/d, 7d/course, for 4–5 courses. If the dose calculated based on the weight of the child exceeded the adult level, the adult dose was usually used. After the clinical symptoms of the child were relieved, the dosage of the drug was reduced.

Children in the combined group received methimazole on the same basis as in the traditional group in combination with 50 µg of selenium (Guangzhou Shanyuantang Health Technology Co., Ltd., approval number: Shijianbei 201744000090) orally, 2 times/d,7 d/course, lasting 4–5 courses.

Blood was collected from all children before and after treatment for 6 mo. Three milliliters of peripheral venous blood was centrifuged in a KH19A centrifuge (Hunan Kaida Scientific Instrument Co., Ltd.) at 4000 r/min with a radius of 5 cm for 10 min, and serum was collected. The chemiluminescence method was used to detect the expression levels of TRAb and anti-thyroid peroxidase antibody (TPOAb) in children using a kit provided by Mingde Biotechnology Co., Ltd according to the manufacturer's instructions. The reference range for normal TRAb was 0–1.75 mIU/L; the reference range for normal TPOAb was 3.0–6.0 pmol/L; and the levels of IL-6, IL-8 and FT4 were determined by an enzyme-linked immunosorbent assay kit (Shanghai Enzyme United Biotechnology Co., Ltd.). The reference range for normal FT4 was 10–31 pmol/L.

***Evaluation criteria for effects and indicators***

The efficacy evaluation criteria were as follows: markedly effective: disappearance of symptoms, weight gain, normal pulse rate, and normal thyroid function; effective: improved symptoms, weight gain, improved pulse rate, and improved thyroid function; invalid: failure to meet the above criteria.

***Statistical analysis***

Statistical analysis uses SPSS22.0 software, measurement data uses mean ± SD, multi-group comparison uses analysis of variance, pairwise comparison uses LSD-*t* test; count data comparison uses *χ*2 test. Inspection level = 0.05.

**RESULTS**

***Comparison of the treatment effect of the two groups of children***

Comparing the treatment effect of the two groups of children, it was found that the treatment efficiency of the children in the combination group was significantly higher than that of the control group. In the combination group, 25 children had a significant therapeutic effect, 20 children had an effective value, and the total effective rate was 84.9%. In the traditional group, 16 cases were markedly effective, 14 cases were effective, the total effective rate was 60.0%, and the difference was statistically significant (*P* < 0.05) (Table 1).

***Comparison of thyroid volume between the two groups of children before and after treatment***

The thyroid volume of the two groups of children before and after treatment showed that the volumes of both groups of children decreased significantly after treatment, and the thyroid volume of the children in the combination group (6.37 ± 1.06) was significantly lower than that of the traditional group (6.92 ± 1.03) (*P* < 0.05) (Table 2).

***Comparison of inflammatory indexes between the two groups of children before and after treatment***

The levels of interleukin-6 (IL-6), IL-8 in the serum of the two groups of children were detected before and after treatment, and it was found that the levels of IL-6, IL-8 in the two groups of children were significantly decreased after treatment, and the levels of inflammatory indexes in the serum of the children in the combination group (6.19 ± 1.26 pg/mL, 293.62 ± 20.93 pg/mL) significantly lower than the traditional group (7.61 ± 1.13 pg/mL, 332.78 ± 87.07 pg/mL) (*P* < 0.05, Table 3).

***Comparison of serum TRAb, TPOAb and FT4 before and after treatment in the two groups of children***

The serum levels of serum TRAb, TPOAb, FT4 in the two groups of children before and after treatment were detected. It was found that serum TRAb, TPOAb, FT4 in the two groups were significantly decreased after treatment, and the TRAb, TPOAb, FT4 levels in the combined group (312.77 ± 44.73 μ/mL, 238.42 ± 83.08 μ/mL, 28.39 ± 4.57 pmol/L) were significantly lower the traditional group (617.61 ± 104.05 μ/mL, 332.78 ± 87.07 μ/mL, 24.63 ± 3.96 pmol/L) (*P* < 0.05, Table 4).

***Comparison of the time taken for FT4 to return to normal in the two groups***

Follow-up of the two groups of children found that, compared with the traditional group, it took less time for the FT4 of the combined group to return to the normal level (*P* < 0.05) (Table 5).

**DISCUSSION**

The clinical cause of Graves’ disease has not yet been clarified, but recent studies have reported obvious family clustering phenomena[8,9], suggesting genetic or related factors. In addition, children with the disease often have autoimmune diseases such as anemia, diabetes, and reduced adrenal function. Therefore, it is speculated that environmental factors such as infection and excessive intake of iodide in the diet may also be related to the disease[10].

Very young children with this type of thyroiditis have obvious symptoms of hyperthyroidism. Commonly used medications for children include thyroid hormone preparations, antithyroid drugs, and adrenal cortex hormones[11,12]. In the present study, the effect of the combined treatment was significantly better than that of the traditional treatment, indicating that methimazole + selenium regimen is an effective treatment regimen for Graves’ disease. Methimazole is an antithyroid drug that inhibits the expression of peroxidase in the thyroid, thereby blocking the coupling of the iodide oxidant to tyrosine in the gland and ultimately inhibiting the production of thyroxine and triiodothyronine[13]. Selenium is an electron donor for glutathione peroxidase, which can induce the conversion of oxidized glutathione to reduced glutathione. Supplementing selenium can effectively enhance the antioxidant capacity of the thyroid, remove reactive oxygen intermediates, and reduce oxidative damage to thyroid cells, preventing hypothyroidism and playing a balancing role[14]. In addition, the addition of selenium can also reduce the amount of hyperthyroidism medication, avoid excessive treatment and cause hypothyroidism.

TRAb is a thyroglobulin-specific antibody synthesized by the human immune system, and TPOAb is an autoantibody mediated by thyroid peroxidase. Abnormal expression of TRAb and TPOAb is closely related to the occurrence and development of autoimmune thyroid diseases. TRAb and TPOAb are commonly used as clinical markers for the detection of immune disorders[15].

In the present study, serum TRAb and TPOAb levels decreased in both groups of children after treatment but were significantly higher in the combined treatment group than in the traditional treatment group, indicating that the combined regimen is more advantageous in terms of immune balance than methimazole alone. One possible reason is that methimazole has antioxidant and immunoregulatory functions[16]. Animal experiments show that methimazole inhibits the synthesis of antibodies by B lymphocytes and induces the expression of thyroid-stimulating antibodies in the blood, thereby maintaining suppressor T cells. Selenium deficiency inhibits the expression of CD8+ T cells, enhances the function of helper T cells, causes B lymphocytes to synthesize a large number of antithyroid antibodies, promotes the activation of thyroid peroxidase, and ultimately damages thyroid tissue. Selenium supplementation can effectively improve these pathological and physiological changes[17,18]. In addition, selenium supplementation can effectively enhance the antioxidant capacity of the thyroid gland, reduce thyroid cell damage, inhibit the expression of thyroglobulin and thyroid peroxidase, and improve the immune status of children.

FT4 is commonly used as in indicator of thyroid function in *in vitro* tests[19]. In the present study, the time for FT4 to return to normal levels was shorter in the combined group than in the traditional group, indicating that the combined dosing regimen can effectively restore children's thyroid function. Although eye improvement was observed in both groups of children after treatment, eye protrusion was significantly lower in the combined group than in the traditional group, indicating that the combined drug regimen also effectively improved the symptoms of hyperthyroidism in the children. Studies have shown that selenium supplementation plays an important role in the treatment of thyroiditis in children. On this basis, we found that methimazole + selenium has a significantly higher therapeutic effect than simple selenium supplementation in children to restore immune balance, improve the symptoms of hyperthyroidism, and restore thyroid function[20].

**CONCLUSION**

In summary, methimazole combined with selenium can effectively treat Graves’ disease, reduce the expression levels of TRAb and TPOAb, and improve thyroid function in children. This regimen warrants further clinical research.

**ARTICLE HIGHLIGHTS**

***Research background***

Thyroglobulin antibody is a common antibody in the serum of children with autoimmune thyroid disease. Anti-thyroid peroxidase antibody (TPOAb) is an indicator closely related to thyroid immune damage.

***Research motivation***

This study explored the therapeutic effects of the two methods, and to detect the changes in serum anti-thyroglobulin antibody (TRAb) and TPOAb levels of the two groups of children before and after treatment.

***Research objectives***

This study aimed to explore the clinical efficacy of methimazole combined with selenium in the treatment of toxic diffuse goiter (Graves’ disease) in children.

***Research methods***

In this study, 103 children with Graves’ disease treated in our hospital were selected and divided into traditional group and combination group according to the treatment method.

***Research results***

The levels of interleukin (IL)-6, IL-8, TRAb, TPOAb and free thyroxine were significantly lower in the combined group than in the traditional group.

***Research conclusions***

The clinical efficacy of combined therapy provides a solid theoretical basis for Graves’ clinical diagnosis and treatment.

***Research perspectives***

This regimen warrants further clinical research.

**REFERENCES**

1 **Ch'ng TW**, Chin VL. Challenging diagnosis of thyroid hormone resistance initially as Hashimoto's thyroiditis. *J Pediatr Endocrinol Metab* 2019; **32**: 203-206 [PMID: 30681972 DOI: 10.1515/jpem-2018-0284]

2 **Subekti I**, Pramono LA. Current Diagnosis and Management of Graves' Disease. *Acta Med Indones* 2018; **50**: 177-182 [PMID: 29950539]

3 **Lai X**, Xia Y, Zhang B, Li J, Jiang Y. A meta-analysis of Hashimoto's thyroiditis and papillary thyroid carcinoma risk. *Oncotarget* 2017; **8**: 62414-62424 [PMID: 28977955 DOI: 10.18632/oncotarget.18620]

4 **Azizi F**, Takyar M, Madreseh E, Amouzegar A. Long-term Methimazole Therapy in Juvenile Graves' Disease: A Randomized Trial. *Pediatrics* 2019; **143** [PMID: 31040197 DOI: 10.1542/peds.2018-3034]

5 **Jeong SH**, Hong HS, Lee JY. The association between thyroid echogenicity and thyroid function in pediatric and adolescent Hashimoto's thyroiditis. *Medicine (Baltimore)* 2019; **98**: e15055 [PMID: 30946351 DOI: 10.1097/MD.0000000000015055]

6 **Won JH**, Lee JY, Hong HS, Jeong SH. Thyroid nodules and cancer in children and adolescents affected by Hashimoto's thyroiditis. *Br J Radiol* 2018; **91**: 20180014 [PMID: 29595320 DOI: 10.1259/bjr.20180014]

7 **Wang D**, Chen J, Zhang H, Zhang F, Yang L, Mou Y. Role of Different CD40 Polymorphisms in Graves' Disease and Hashimoto's Thyroiditis. *Immunol Invest* 2017; **46**: 544-551 [PMID: 28742400 DOI: 10.1080/08820139.2017.1319382]

8 **Brčić L**, Barić A, Gračan S, Brekalo M, Kaličanin D, Gunjača I, Torlak Lovrić V, Tokić S, Radman M, Škrabić V, Miljković A, Kolčić I, Štefanić M, Glavaš-Obrovac L, Lessel D, Polašek O, Zemunik T, Barbalić M, Punda A, Boraska Perica V. Genome-wide association analysis suggests novel loci for Hashimoto's thyroiditis. *J Endocrinol Invest* 2019; **42**: 567-576 [PMID: 30284222 DOI: 10.1007/s40618-018-0955-4]

9 **Kahaly GJ**. Management of Graves Thyroidal and Extrathyroidal Disease: An Update. *J Clin Endocrinol Metab* 2020; **105** [PMID: 32929476 DOI: 10.1210/clinem/dgaa646]

10 **Krysiak R**, Kowalcze K, Okopień B. Selenomethionine potentiates the impact of vitamin D on thyroid autoimmunity in euthyroid women with Hashimoto's thyroiditis and low vitamin D status. *Pharmacol Rep* 2019; **71**: 367-373 [PMID: 30844687 DOI: 10.1016/j.pharep.2018.12.006]

11 **Ciurleo R**, Sessa E, Marino S, D'Aleo G, Bramanti P, Rifici C. Acute exacerbation of Hashimoto's thyroiditis in a patient treated with dimethyl fumarate for multiple sclerosis: A case report. *Medicine (Baltimore)* 2019; **98**: e15185 [PMID: 31027063 DOI: 10.1097/MD.0000000000015185]

12 **Zhao ZL**, Wang SM, Shao CY, Fu Y. Ascher syndrome: a rare case of blepharochalasis combined with double lip and Hashimoto's thyroiditis. *Int J Ophthalmol* 2019; **12**: 1044-1046 [PMID: 31236366 DOI: 10.18240/ijo.2019.06.26]

13 **Uc ZA**, Gorar S, Mizrak S, Gullu S. Irisin levels increase after treatment in patients with newly diagnosed Hashimoto thyroiditis. *J Endocrinol Invest* 2019; **42**: 175-181 [PMID: 29777516 DOI: 10.1007/s40618-018-0899-8]

14 **Peng Q**, Niu C, Zhang M, Peng Q, Chen S. Sonographic Characteristics of Papillary Thyroid Carcinoma with Coexistent Hashimoto's Thyroiditis: Conventional Ultrasound, Acoustic Radiation Force Impulse Imaging and Contrast-Enhanced Ultrasound. *Ultrasound Med Biol* 2019; **45**: 471-480 [PMID: 30528690 DOI: 10.1016/j.ultrasmedbio.2018.10.020]

15 **Suzuki N**, Yoshihara A, Yoshimura Noh J, Kinoshita K, Ohnishi J, Saito M, Sugino K, Ito K. TRAb elevations occurred even in the third trimester; a case of a mother of a child with neonatal thyroid dysfunction, who received radioactive iodine therapy for Graves' disease. *Endocr J* 2020; **67**: 1019-1022 [PMID: 32522908 DOI: 10.1507/endocrj.EJ20-0039]

16 **Barić A**, Brčić L, Gračan S, Škrabić V, Brekalo M, Šimunac M, Lovrić VT, Anić I, Barbalić M, Zemunik T, Punda A, Boraska Perica V. Thyroglobulin Antibodies are Associated with Symptom Burden in Patients with Hashimoto's Thyroiditis: A Cross-Sectional Study. *Immunol Invest* 2019; **48**: 198-209 [PMID: 30332318 DOI: 10.1080/08820139.2018.1529040]

17 **Xu B**, Wu D, Ying H, Zhang Y. A pilot study on the beneficial effects of additional selenium supplementation to methimazole for treating patients with Graves’ disease. *Turk J Med Sci* 2019; **49**: 715-722 [PMID: 31023005 DOI: 10.3906/sag-1808-67]

18 **Rodó C**, Deambrogio F, Serra L, Pina S, Sánchez-Duran MÁ. Recurrent fetal thyrotoxicosis in woman with history of Hashimoto's thyroiditis. *Ultrasound Obstet Gynecol* 2017; **50**: 801-802 [PMID: 28508540 DOI: 10.1002/uog.17526]

19 **Li Q**, Lu M, Wang NJ, Chen Y, Chen YC, Han B, Li Q, Xia FZ, Jiang BR, Zhai HL, Lin DP, Lu YL. Relationship between Free Thyroxine and Islet Beta-cell Function in Euthyroid Subjects. *Curr Med Sci* 2020; **40**: 69-77 [PMID: 32166667 DOI: 10.1007/s11596-020-2148-6]

20 **McLachlan SM**, Aliesky H, Banuelos B, Hee SSQ, Rapoport B. Variable Effects of Dietary Selenium in Mice That Spontaneously Develop a Spectrum of Thyroid Autoantibodies. *Endocrinology* 2017; **158**: 3754-3764 [PMID: 28938453 DOI: 10.1210/en.2017-00275]

**Footnotes**

**Institutional review board statement:** This study was approved by the Ethics Committee of the Quanzhou Maternal and Child Hospital.

**Informed consent statement:** Patients were not required to give informed consent to the study because the analysis used anonymous clinical data that were obtained after each patient agreed to treatment by written consent.

**Conflict-of-interest statement:** No conflict of interest.

**Data sharing statement:** No additional data are available.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Unsolicited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review started:** October 22, 2021

**First decision:** November 17, 2021

**Article in press:** December 22, 2021

**Specialty type:** Pediatrics

**Country/Territory of origin:** China

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B, B

Grade C (Good): 0

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Taieb D, Todsen T **S-Editor:** Wang JL **L-Editor:** A **P-Editor:** Wang JL

**Table 1 Comparison of therapeutic effects between the two groups, *n* (%)**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Group** | **Cases** | **Markedly effective** | **Efficient** | **Invalid** | **Total effective rate** |
| Joint group | 53 | 25 | 20 | 8 | 45 (84.9) |
| Traditional group | 50 | 16 | 14 | 20 | 30 (60.) |
| *χ*2 |  |  |  |  | 8.062 |
| *P* value |  |  |  |  | 0.005 |

**Table 2 Comparison of thyroid volume between the two groups before and after treatment (mean ± SD)**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Group** | **Cases** | **Thyroid volume** | | ***t* value** | ***P* value** |
| **Before treatment** | **After treatment** |
| Joint group | 53 | 10.25 ± 3.21 | 6.37 ± 1.06 | 8.142 | 0.000 |
| Traditional group | 50 | 10.87 ± 3.15 | 6.92 ± 1.03 | 8.449 | 0.000 |
| *t* value |  | 0.981 | 2.693 |  |  |
| *P* value |  | 0.162 | 0.004 |  |  |

**Table 3 Comparison of inflammatory indexes between the two groups before and after treatment (mean ± SD)**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Group** | **Cases** | **IL-6 (pg/mL)** | | **IL-8 (pg/mL)** | |
| **Before treatment** | **After treatment** | **Before treatment** | **After treatment** |
| Joint group | 53 | 13.62 ± 3.56 | 6.19 ± 1.26a | 351.47 ± 23.89 | 293.62 ± 20.93a |
| Traditional group | 50 | 12.93 ± 3.17 | 7.61 ± 1.13a | 353.69 ± 23.12 | 332.78 ± 87.07a |
| *t* value |  | 1.03 | 6.08 | 0.478 | 3.179 |
| *P* value |  | 0.15 | 0.000 | 0.316 | 0.000 |

a*P* < 0.05 *vs* before treatment.

IL-6: Interleukin-6; IL-8: Interleukin-8.

**Table 4 Table 4 Comparison of Serum anti-thyroglobulin, anti-thyroid peroxidase antibody, free thyroxine between the two groups before and after treatment (mean ± SD)**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Group** | **Cases** | **TRAb (μ/mL)** | | **TPOAb (μ/mL)** | | **FT4 (pmol/L)** | |
| **Before treatment** | **After treatment** | **Before treatment** | **After treatment** | **Before treatment** | **After treatment** |
| Joint group | 53 | 723.62 ± 124.6 | 312.77 ± 44.73a | 429.48 ± 93.89 | 238.42 ± 83.08a | 56.54 ± 5.56 | 28.39 ± 4.57a |
| Traditional group | 50 | 722.93 ± 123.2 | 617.61 ± 104.05a | 429.74 ± 93.97 | 332.78 ± 87.07a | 56.38 ± 5.07 | 24.63 ± 3.96a |
| *t* value |  | 0.028 | 19.51 | 1.984 | 5.63 | 0.152 | 4.451 |
| *P* value |  | 0.488 | 0.000 | 0.494 | 0.000 | 0.879 | 0.000 |

a*P* < 0.05 *vs* before treatment.

TRAb: Serum anti-thyroglobulin; TPOAb: Anti-thyroid peroxidase antibody; FT4: Free thyroxine.

**Table 5 Comparison of time taken for free thyroxine to return to normal between the two groups (mean ± SD)**

|  |  |  |
| --- | --- | --- |
| **Group** | **Cases** | **Time to return to normal (d)** |
| Joint group | 53 | 90.67 ± 8.54 |
| Traditional group | 50 | 123.5 ± 15.14 |
| *t* value |  | 13.65 |
| *P* value |  | 0.000 |



Published by **Baishideng Publishing Group Inc**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-3991568

**E-mail:** bpgoffice@wjgnet.com

**Help Desk:** https://www.f6publishing.com/helpdesk

https://www.wjgnet.com



**© 2022 Baishideng Publishing Group Inc. All rights reserved.**